| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-719 | |
| Phytochemical name or plant extracts | Saxifragifolin C | |
| PMID | 26965415 | |
| Literature evidence | The purpose of this study is to evaluate the in vitro anti-tumor activity of Saxi C in human breast cancer cells. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid saponins | |
| Source of phytochemicals or plant Extracts | Androsace umbellata | |
| Geographical availability | N. Pakistan to Russian Far East and Philippines (N. Luzon), NE. New Guinea | |
| Plant parts | Dried whole plants | |
| Other cancers | Breast cancer | |
| Target gene or protein | p38 MAPK, ERK 1/2, JNK | |
| Gene or Protein evidence | the phosphorylation of ERK 1/2, p38 MAPK and JNK increased after treatment with 7 μg/ml of Saxi C in both MCF-7 cells and MDA-MB-231 cells. | |
| Target pathways | Saxifragifolin C induces apoptosis via the MAPK signaling pathway | |
| IC50 | 7.75 μg/ml against MCF-7 3.02 μg/ml against MDA-MB-231 | |
| Potency | Taken together, Saxi C induced apoptosis in MCF-7 cells and MDA-MB-231 cells via different regulatory mechanisms, and ERα status might be essential for regulating Saxi C-induced apoptosis in breast cancer cells. Thus, Saxi C is a potential chemotherapeutic agent in breast cancer. | |
| Cell line/ mice model | MCF-7, MDA-MB-231 | |
| Additional information | Saxi C could therefore be effective for the prevention and treatment of both ER-positive and ER-negative breast cancer. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:700464-1 | |
| Safety | NA |